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Objective Recently, a novel score for risk stratification of patients with pulmonary embolism (PE)—
the HOPPE score—was derived. We aimed to externally validate the HOPPE score in emergency 
department-diagnosed PE, using SpO2 as a surrogate for PaO2—the modified HOPPE score.
Methods Retrospective observational study of adult patients with an emergency department di-
agnosis of PE was performed. Data collected included demographics, co-morbidities, clinical 
features, electrocardiogram and test results, in-hospital mortality and non-fatal major adverse 
clinical events (MACE; survived cardiac arrest, cardiogenic shock or thrombolysis administration). 
The primary outcome of interest was clinical performance of the modified HOPPE score for in-
hospital mortality and the composite outcome of in-hospital death and MACE. A secondary out-
come was comparison of predictive performance between the modified HOPPE score and the 
simplified Pulmonary Embolism Severity Index score.
Results Two hundred and six patients were studied (median age 61, 55% female). There were no 
deaths or MACE in patients with a low risk modified HOPPE score of 0 to 6 (0%; 95% confidence 
interval, 0% to 1.8%). Negative predictive value of a low risk score was 100% (95% confidence 
interval, 92.2% to 100%) for in-hospital mortality and for the composite of in-hospital mortality 
or MACE. The modified HOPPE score had similar predictive performance to the simplified Pulmo-
nary Embolism Severity Index score with an area under the curve of 0.88 vs. 0.80 for the com-
posite outcome of in-hospital mortality or MACE (P=0.052). Twenty-eight percent of the pa-
tients were classified as low risk and potentially suitable for management as outpatients.
Conclusion The modified HOPPE score showed good clinical performance. Prospective validation 
is warranted. 
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INTRODUCTION
Pulmonary embolism (PE) is an uncommon condition in emergen-
cy departments (ED) accounting for approximately 1.2% of ED 
presentations for shortness of breath.1 It carries a mortality of 
approximately 4% and a risk of serious non-fatal major adverse 
clinical events (MACE) of approximately a further 2.5%.2 
 There has been a move towards outpatient management of 
low risk PE.3 The keys to safe and effective outpatient treatment 
are appropriate risk stratification and close follow-up.4 The Pul-
monary Embolism Severity Index (PESI) is the most widely vali-
dated risk stratification score—in either its original or simplified 
version. If the PESI score is ≤65 (classified as very low risk) or 
66–85 (low risk) there is a low risk of mortality or morbidity and 
outpatient management can be considered.5 A simplified PESI 
(sPESI) score of 0 has a 1.1% risk of death and a 1.5% risk of re-
current thromboembolism or non-fatal bleeding.6 The PESI score 
in both its forms has been criticized for its reliance on co-mor-
bidity data and the difficulty of obtaining this accurately in the 
ED. The components of the sPESI score are shown in Table 1. 
 Recently a new score has been derived, the HOPPE score—an 
acronym derived from its elements heart rate, oxygenation, systolic 
and diastolic blood pressure and electrocardiogram (ECG) features.2 
Its components are shown in Table 1. In internal and a small exter-
nal validation, low risk patients (score ≤6) had no 30-day mortali-
ty or non-fatal MACE.2 External validation to date has been small 
(total of 82 patients, only 27 low risk). To be clinically acceptable, 
further external validation is required. In addition, the HOPPE score 
relies on the measured arterial partial pressure of oxygen (PaO2) 
obtained by arterial blood gas analysis. This test is painful for pa-
tients and may only be performed in patients with other indicators 
of hypoxia such as low peripheral oxygen saturation on pulse ox-
imetry (SpO2) or respiratory failure. SpO2 has been shown to corre-
late well with PaO2,7 so it may be that SpO2 can be a less invasive 
What is already known
Low risk pulmonary embolism is increasingly treated as outpatients. The Pulmonary Embolism Severity Index is the only 
validated risk stratification tool for pulmonary embolism. A new score (HOPPE) has been proposed.
What is new in the current study
HOPPE score had high predictive value. It performed similarly to the simplified Pulmonary Embolism Severity Index for 
the composite outcome (in-hospital mortality, major adverse events). This score is easily applied in the emergency de-
partment and less reliant on co-morbidity, which is open to missing data and interpretation.
Table 1. Calculation of the modified HOPPE and sPESI scores
HOPPE score
Variable  
cut-offs
Points  
allocated
Heart rate (beats per minute) ≤80 1
81–100 2
>100 3
Oxygenation (%, SpO2 on room air) ≥95 1
90–94 2
<90 3
Systolic blood pressure (mmHg) ≥120 1
100–119 2
<100 3
Diastolic blood pressure (mmHg) ≥80 1
65–79 2
<65 3
ECG score groupa) <2 1
2–4 2
>4 3
Minimum score is 5; maximum score is 15
Low risk ≤6
Intermediate risk 7–10
High risk >10
sPESI score
Age >80 years 1
History of cancer 1
History of chronic cardiopulmonary disease 1
Heart rate >110 beats per minute 1
Systolic blood pressure <100 mmHg 1
Oxygen saturation <90% 1
Minimum score is 0; maximum score is 6
   Low risk 0
   Non-low risk  ≥1
sPESI, simplified Pulmonary Embolism Severity Index; ECG, electrocardiogram.
a)ECG score calculation: 1 point for incomplete right bundle branch block, 2 points 
for tachycardia, 3 points for complete right bundle branch block, 4 points each 
for T wave inversion in V1-3 or S1Q3T3 pattern.
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measure of oxygenation for the purposes of this score.
 The primary objective of this study was to validate the HOPPE PE 
risk score in ED-diagnosed PE, using SpO2 as a surrogate for PaO2 in 
the score (the modified HOPPE score) for the outcomes of in-hospi-
tal mortality or the composite outcome of in-hospital mortality or 
MACE. The secondary objective was to compare the clinical perfor-
mance of the modified HOPPE score with the sPESI score.
METHODS
Study design and setting
We performed a retrospective observational study by medical re-
cord review. It was undertaken in the EDs of two university-affil-
iated urban community teaching hospitals with a combined 
adult ED census of approximately 100,000. Participants were all 
adult patients with an ED diagnosis of PE (as coded on ED data 
management system) between 1 January 2014 and 30 June 
2017 who were admitted to the hospital for treatment. Exclu-
sion criteria were age <18 years, unconfirmed diagnosis of PE 
(confirmation by computed tomography pulmonary angiogram 
or ventilation-perfusion scan was required), missing ECG or 
medical record, previous inclusion and patients who were inter-
hospital transfers.
Data collection
Collected data included demographics, PE confirmation methods, 
past medical history of cancer, heart failure or chronic lung dis-
ease (defined as a documented history of chronic obstructive pul-
monary disease, asthma requiring daily medication, bronchiecta-
sis, pulmonary fibrosis or cystic fibrosis), vital signs (heart rate, 
blood pressure, respiratory rate, SpO2 on room air), ECG analysis, 
troponin and blood gas analysis results (if taken), in-hospital 
mortality, non-fatal MACE (defined as survived cardiac arrest, car-
diogenic shock or administration of thrombolysis). With respect to 
the clinical features, we used the first recorded measurements in 
the ED. For SpO2 if a room air reading was not available in the ED 
records we used first one recorded by paramedics.
 Data was collected onto a piloted, project-specific data form 
by trained clinical researchers (ED doctors and specialist ED nurs-
es) with access to a project-specific data dictionary. Data collec-
tors were not blinded to study hypotheses. 
Outcomes of interest
Outcomes of interest were 1) clinical performances (sensitivity, 
specificity, negative predictive value [NPV]) of the modified 
HOPPE score for in-hospital mortality and the composite out-
come of in-hospital mortality or non-fatal MACE and 2) com-
parison of the predictive performance of the modified HOPPE 
score to the sPESI score. 
Analysis
Categorical variables are reported as number and percentages, 
with 95% confidence intervals (CIs) as required. Continuous vari-
ables are reported as median and interquartile range. Analysis is 
descriptive for clinical performance. Receiver operating charac-
teristic curve analysis was used to compare the modified HOPPE 
score and the sPESI score. All analyses were performed using Anal-
yse-It for Excel (https://analyse-it.com; Analyse-it Software, Leeds, 
UK). The previous study2 reported NPV for 30-day mortality of 
95% to 96%. Based on this, 160 patients were required to give a 
confidence interval +/- 5% for NPV of the outcome in-hospital 
mortality or composite mortality or MACE. Inter-rater reliability 
was assessed for 20 of cases. This was analyzed using kappa anal-
ysis and percent agreement. 
Ethical approval
This study was approved by the Western Health Low Risk Ethics 
Panel (QA 2019.085). Patient consent for data collection was not 
required.
RESULTS
Two hundred and six patients were studied. Sample derivation is 
shown in Fig. 1. Median age was 61 years and 55% were female. 
Characteristics of the patients and their modified HOPPE risk score 
distribution are shown in Table 2. Fifty eight (28.2%) were classi-
Fig. 1. Sample derivation. PE, pulmonary embolism; ECG, electrocardio-
gram; RVD, right ventricular dysfunction.
296 Excluded
    192 No confirmed PE
      42 Missing ECG
      36 Not admitted/transferred
      19 Already included
        4 Missing medical record
        3 Age <18 years
206 Included
4 In-hospital 
mortalities  
(2%)
27 Composite 
major adverse 
events (13%)
62 Composite major 
adverse events or 
RVD (30%)
502 Screened for inclusion
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Table 2. Patient demographics and clinical features
Parameter  Value
Age (yr)         61 (44–72)
Sex, female 114 (55)
Patient characteristics
Confirmation method CT pulmonary angiogram 150 (66.4%–78.4%)
Ventilation-perfusion scan 54 (20.7%–32.6%)
Both 2 (0.27%–3.5%)
Heart rate distribution (beats per minute) ≤80 66 (26.1%–38.7%)
81–100 65 (25.6%–38.2%)
>100 75 (30.1%–43.2%)
Oxygenation (SpO2 on air) ≥95% 120 (51.4%–64.8%)
90–94% 55 (21.1%–33.1%)
<90% 31 (10.8%–20.6%)
Systolic blood pressure (mmHg) ≥120 156 (69.4%–81.1%)
100–119 41 (15%–25.9%)
<100 9 (2.3%–8.1%)
Diastolic blood pressure (mmHg) ≥80 98 ( 40.9%–54.4%)
65–79 70 (27.9%–40.7%)
<65 38 (13.8%–24.3%)
Electrocardiogram score <2 124 (53.4%–66.6%)
2–4 44 (16.3%–27.5%)
>4 38 (13.8%–24.3%)
Risk score distribution—modified HOPPE ≤6 (low) 58 (22.5%–34.7%)
7–10 (intermediate) 113 (48%–61.5%)
>10 (high) 35 (12.5%–22.7%)
Risk score distribution—sPESI  0 (low) 102 (42.8%–56.3%)
≥1 (high) 104 (43.7%–57.3%)
Outcome
In-hospital mortality 4 (0.8%–4.8%)
Nonfatal major adverse clinical event 19 (6%–14%)
Right ventricular dysfunction on investigation 58 (22.5%–34.7%)
Values are presented as median (interquartile range); number (%); or number (%), 95% confidence interval.
CT, computed tomography; sPESI, simplified Pulmonary Embolism Severity Index.
Table 3. Outcome by modified HOPPE and sPESI score category
In-hospital mortality In-hospital MACE In-hospital mortality or MACE Right ventricular dysfunction
Modified HOPPE score
   ≤6 (low) 0/58 (0), 0%–6.2% 0/58 (0), 0%–6.2% 0/58 (0), 0%–6.2% 1/58 (1.7), 0.3%–9.1%
   7–10 (intermediate) 1/113 (0.8), 0.2%–0.5%  4/113 (3.5), 1.4%–8.8% 5/113 (4.4), 1.9%–9.9% 34/113 (30), 22.4%–39.1% 
   >10 (high) 3/35 (8.6), 3%–22.4% 11/35 (31.4), 18.6%–48% 14/35 (40), 25.6%–56.4% 23/35 (35.7), 49.2%–79.2%
sPESI
   0 (low) 1/102 (1), 0.2%–5.4%  2/102 (2), 0.5%–6.9%  3/102 (2.9), 1%–8.3% 12/102 (11.8), 6.9%–19.4%
   ≥1 (high) 3/104 (2.9), 1%–8.1% 13/104 (12.5), 7.5%–20.2% 16/104 (15.4), 9.7%–23.5% 46/104 (44.2), 35%–53.8%
Values are presented as number (%), 95% confidence interval.
MACE, major adverse clinical events; sPESI, simplified Pulmonary Embolism Severity Index. 
fied as low risk by the modified HOPPE score. Inpatient mortality 
was 4/206 (1.9%; 95% CI, 0.8% to 4.9%). A further 15 patients 
suffered non-fatal MACE. The distribution of non-fatal MACE is 
shown in Supplementary Table 1. 
 Outcome by modified HOPPE score risk category classification 
is shown in Table 3. There were no deaths or MACE in patients 
with a modified HOPPE score of ≤6 (low risk group, 0%; 95% CI, 
0% to 6.2%). For in-hospital mortality, the modified HOPPE score 
had sensitivity of 100% (95% CI, 39.6% to 100%), specificity of 
28.7% (95% CI, 22.7% to 35.6%) and NPV of 100% (95% CI, 92.2% 
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to 100%). For the composite outcome of in-hospital mortality or 
MACE, the modified HOPPE score had sensitivity of 100% (95% 
CI, 79.1% to 100%), specificity of 31% (95% CI, 24.6% to 38.2%) 
and NPV of 100% (95% CI, 92.2% to 100%) (Table 4).
 The area under the receiver operating characteristic curve of 
sPESI score for in-hospital mortality was 0.79 (95% CI, 0.61 to 
0.96) and for the composite outcome of in-hospital mortality or 
MACE was 0.88 (95% CI, 0.80 to 0.95). In comparison to the sPESI 
score, the modified HOPPE score had similar predictive perfor-
mance with area under the receiver operating characteristic 
curve of 0.88 vs. 0.80 for the composite outcome of in-hospital 
mortality or MACE (P=0.052) (Fig. 2).
 Inter-rater reliability for data collection is shown in Supple-
mentary Table 2. Agreement was 100% for the items PE con-
firmed by computed tomography pulmonary angiogram, pres-
ence of incomplete right bundle branch block, presence of S1Q3T3 
pattern on ECG, in-hospital mortality and occurrence of non-fa-
tal adverse events. Agreement was moderate-to-good for the 
variables heart rate group, oxygen saturation group and systolic 
blood pressure group.
DISCUSSION
Outpatient treatment of venous thromboembolism (including, PE 
and deep venous thrombosis) is becoming more common.4 Out-
patient treatment releases capacity in hospitals, reduces patient 
exposure to hospital-acquired infections and other complications 
associated with hospitalization and is associated with high levels 
of patient satisfaction.8 The keys to safe and effective outpatient 
treatment are appropriate risk stratifications and close follow-up 
arrangements.4
 In this external validation, the modified HOPPE score performed 
well, with very high NPV for in-hospital mortality and the com-
posite outcomes of in-hospital mortality and non-fatal MACE. It 
showed similar predictive performance to the sPESI score for the 
composite outcome of in-hospital mortality and non-fatal MACE. 
Taken together with previous derivation, internal and external 
validation, the data suggests that this score may be useful in as-
sessing which patients with PE may be suitable for treatment in 
the community rather than in hospital.
 The modified HOPPE score has the advantage of being calcu-
lated using variables readily available at the bedside and it is not 
subject to missing data or patient recall error regarding past med-
ical history. It is also not reliant on laboratory tests or advanced 
imaging (such as echocardiography) so may be particularly useful 
in those EDs where these modalities are not available. That the 
modified HOPPE score performed well despite a quite different 
risk score classification distribution in our cohort compared to 
the derivation and validation studies is promising with respect to 
generalizability between populations. While there was a similar 
proportion of low risk patients, the proportion of high-risk patients 
in our study was substantially lower (17% vs. 34%). Reasons for 
this are unclear.
 The modified HOPPE score classified about half as many pa-
tients as low risk compared to that reported for the sPESI score. 
However it did identify a very low risk patient group. The sPESI 
classification would see more patients classified as low risk and 
suitable for outpatient management but at the cost of about 3% 
risk of death or MACE. What level of risk clinicians are prepared 
to accept and which score has better utility and acceptability in 
the ED clinical setting is unknown.
 The modified HOPPE and sPESI scores share three key variables—
Fig. 2. Comparison of receiver operating characteristic curves for sim-
plified Pulmonary Embolism Severity Index (sPESI) and modified HOPPE 
scores with respect to the composite outcome of in-hospital mortality 
or major adverse clinical event.
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Table 4. Clinical performance of the low risk modified HOPPE score
Sensitivity (95% CI) Specificity (95% CI) Negative predictive value (95% CI)
In-hospital mortality 100% (39.6%–100%) 28.2% (22.2%–34.9%) 100% (92.2%–100%)
In-hospital mortality or MACE 100% (82.8%–100%) 28.2% (22.2%–34.9%) 100% (92.2%–100%)
CI, confidence interval; MACE, major adverse clinical event.
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pulse rate, systolic blood pressure and oxygen saturation. All have 
high face validity and have been shown to be associated with out-
come.2,9 A potential criticism of the HOPPE score is that it does 
not take into account co-morbidities which may be an important 
factor in physician decision-making. Incorporation of co-morbidi-
ties in the sPESI score has been seen as a weakness of that score. 
The justification given for omitting co-morbidities from the HOPPE 
score was difficulty getting accurate data for the co-morbidity 
components of the score, with missing data potentially resulting 
in an under-estimation of true risk. Risk stratification tools are 
useful to inform and support physician decision-making but do 
not supplant the responsibility of clinicians to make decisions con-
sidering all of the available data and the individual patient context. 
 The proportion of patients with low risk PE treated as outpa-
tients is small and appears to be changing slowly over time de-
spite evidence of safety and feasibility.4,10 Reasons may include 
lack of confidence in the evidence, medicolegal concerns and lack 
of systems to support outpatient care of these patients. Use of 
further risk stratification with investigation for right ventricular 
dysfunction and troponin and lactate assays may help overcome 
the first two of these concerns, as abnormal results on these tests 
have been shown to be associated with poorer outcomes.11,12 
 This study has some limitations that should be considered when 
interpreting the results. It was conducted at a single health ser-
vice, so results may not be generalizable. Data were collected ret-
rospectively, so it may be subject to missing data.13 There may 
also have been an element of subjectivity in ECG interpretation, 
especially as data collectors were not blinded to the study objec-
tives. Confidence intervals are wide due to unexpectedly low 
mortality and MACE. Our study did not assess either utility or 
usefulness of the score due to study design. The score was not 
used in practice. Cases of PE may have been missed in the ED. 
However, this is the ‘real world’ of ED practice.
 The clinical implications of our findings are limited as the mod-
ified HOPPE score has not been subjected to prospective external 
validation. Given its good performance in this study, we think fur-
ther research is justified. 
 In this study, the modified HOPPE score showed good clinical 
performance. Given its ease of use in the ED setting and good 
predictive performance, further research to validate it prospec-
tively with a view to incorporation into treatment pathways for 
PE is justified. 
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Supplementary Table 1. Distribution of major adverse clinical events 
Event Number (%) Overlap with other major adverse events
Survived cardiac arrest   0 Not applicable Not applicable
Cardiogenic shock   7 Thrombolysis 6
Thrombolysis 14 Cardiogenic shock 6
Note may have more than 1 event.
Supplementary Table 2. Inter-rater reliability analysis
Data variable Kappa Percent agreement (95% CI)
PE confirmed by CTPA 1.00 100% (80%–100%) 
Heart rate group 0.66 80% (58%–92%)
Oxygen saturation group 0.81 85% (64%–95%)
Systolic blood pressure group 0.81 90% (70%–97%)
Presence of incomplete RBBB 1.00 100% (80%–100%)
Presence of S1Q3T3 pattern 1.00 100% (80%–100%)
Presence of T wave inversion in V1-3 0.50 90% (79%–97%)
In-hospital mortality 1.00 100% (80%–100%)
Non-fatal adverse event 1.00 100% (80%–100%)
CI, confidence interval; PE, pulmonary embolism; CTPA, computed tomography 
pulmonary angiogram; RBBB, right bundle branch block.
